Biomea Fusion, Inc. (BMEA)
NASDAQ: BMEA · Real-Time Price · USD
4.250
+0.275 (6.92%)
At close: Jan 21, 2025, 4:00 PM
4.190
-0.060 (-1.41%)
After-hours: Jan 21, 2025, 7:59 PM EST
Biomea Fusion Employees
Biomea Fusion had 103 employees as of December 31, 2023. The number of employees increased by 20 or 24.10% compared to the previous year.
Employees
103
Change (1Y)
20
Growth (1Y)
24.10%
Revenue / Employee
n/a
Profits / Employee
-$1,398,136
Market Cap
154.01M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 103 | 20 | 24.10% |
| Dec 31, 2022 | 83 | 32 | 62.75% |
| Dec 31, 2021 | 51 | 39 | 325.00% |
| Dec 31, 2020 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
BMEA News
- 5 weeks ago - Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday? - Benzinga
- 5 weeks ago - Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes - GlobeNewsWire
- 5 weeks ago - Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D) - GlobeNewsWire
- 5 weeks ago - Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) - GlobeNewsWire
- 6 weeks ago - Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia - GlobeNewsWire
- 6 weeks ago - Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia - GlobeNewsWire
- 7 weeks ago - Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into Biomea Fusion, Inc. For Securities Law Violations - Accesswire